Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

High nasopharyngeal viral load in SARS-CoV-2 Omicron-induced infection

In a recent study posted to the Research Square* pre-print server, a team of researchers from Italy and the United States (US) retrospectively reviewed and compared viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and previous SARS-CoV-2 strain-induced infection.

23 Feb 2022

More evidence vaccines prevent ICU admission and mortality from SARS-CoV-2

In a recent study posted to the medRxiv* preprint server, researchers estimated the comparative virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between the vaccinated and unvaccinated subjects hospitalized with coronavirus disease 2019 (COVID-19) in Canada.

23 Feb 2022

Closing bars and restaurants does not appear to have suppressed COVID-19 in Japan

In a recent study posted in the Research Square* preprint server, which is under consideration at the journal Scientific Reports, a team of researchers conducted a longitudinal survey in 11 Japanese prefectures to evaluate whether early closure of full-service restaurants and bars reduced the incidence and symptoms of coronavirus disease 2019 (COVID-19) during February 2021.

23 Feb 2022

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

23 Feb 2022

Neural mechanisms of fatigue in COVID-19 convalescents

In a recent study posted to the medRxiv* preprint server, researchers characterized the mechanisms associated with neural dysregulation in post-coronavirus disease (COVID) fatigue (pCF) by evaluating individuals recovered from mild severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

23 Feb 2022

SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

In a recent study posted to the medRxiv* pre-print server, researchers performed genomic monitoring to estimate the magnitude and range of the different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in SARS-CoV-2 reinfection cases among fully vaccinated individuals in Salvador, Bahia, Brazil.

23 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Circulating miR-155 may predict chances of survival in hospitalized COVID-19 patients

Scientists from Israel have recently estimated the levels of circulating microRNAs (miRNAs) in hospitalized coronavirus disease 2019 (COVID-19) patients with the aim of identifying prognostic biomarkers for disease severity. They have identified miR-155, an important regulatory molecule in the immune system, as a potential biomarker to predict COVID-19 severity and mortality.

22 Feb 2022

Omicron neutralizing titers after third BNT162b2 dose are persistent

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine.

22 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022